Transcriptional profile of CAOV2 primary and CAOV2 recurrent cells

We performed RNAseq to study the transcriptional changes of human CAOV2 recurrent vs CAOV2 primary ovarian cancer cells to understand the genetic determinants of ferroptosis response Overall design: CAOV2-GFP/LUC cells (3.5x10^5 per mouse) were injected intraperitoneally into female nude mice with tumor formation monitored weekly using the IVIS in vivo imaging system. Once tumor formation was evident, we initiated treatment with carboplatin (60mg/kg intraperitoneally twice a week for two weeks) and monitored for changes in tumor flux. In this model, tumor signal was reduced following carboplatin treatment but then recurred approximately 2-4 weeks after carboplatin treatment had stopped. Therefore, we refer to the residual tumor cells that eventually emerged as CAOV2R (recurrent). Both CAOV2 primary and CAOV2 recurrent cells are cultured in DMEM+10%FBS before submitting for RNAseq.